Quarcoo, D <br/><br/>
Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice.  [electronic resource] 

 -  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology  Aug 2004 
 - 1314-20 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0954-7894 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2222.2004.02023.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Allergens--pharmacology<br/>Animals<br/>Asthma--drug therapy<br/>Bronchi--immunology<br/>Bronchial Hyperreactivity--immunology<br/>Bronchoalveolar Lavage Fluid--cytology<br/>Female<br/>Imidazoles--therapeutic use<br/>Immunologic Factors--therapeutic use<br/>Interferon-gamma--immunology<br/>Interleukin-12--immunology<br/>Interleukin-4--immunology<br/>Interleukin-5--immunology<br/>Lymphocyte Activation--drug effects<br/>Mice<br/>Mice, Inbred BALB C<br/>Ovalbumin--pharmacology<br/>Th2 Cells--immunology